Prescription medicine
Cobicistat, elvitegravir, emtricitabine and tenofovir alafenamide Brand names: Genvoya
Cobicistat, elvitegravir, emtricitabine and tenofovir alafenamide (Genvoya) is a prescription medicine with an FDA approval on record since 2015. No generic is listed; pharmacies paid $143.35 per Genvoya tablet in the October 7, 2026 NADAC survey.
- No generic listed
- Boxed warning
Check it at the source: the cobicistat, elvitegravir, emtricitabine and tenofovir alafenamide FDA label on DailyMed (effective February 3, 2025, Gilead Sciences, Inc.); the NDA 207561 record on Drugs@FDA; every cobicistat, elvitegravir, emtricitabine and tenofovir alafenamide label on DailyMed.
Highlights of the record
FDA label of February 3, 2025; NDC Directory, Drugs@FDA and Orange Book, October 8, 2026; NADAC October 7, 2026
Boxed warning
POST TREATMENT ACUTE EXACERBATION OF HEPATITIS B.
Severe acute exacerbations of hepatitis B have been reported in patients who are coinfected with HIV-1 and HBV and have discontinued products containing emtricitabine and/or tenofovir disoproxil fumarate (TDF), and may occur with discontinuation of GENVOYA. Hepatic function should be monitored closely with both clinical and laboratory follow-up for at least several months in patients who are coinfected with HIV-1 and HBV and discontinue GENVOYA. If appropriate, anti-hepatitis B therapy may be warranted [see Warnings and Precautions (5.1) ]. WARNING: POST TREATMENT ACUTE EXACERBATION OF HEPATITIS B See full prescribing information for complete boxed warning. Severe acute exacerbations of hepatitis B have been reported in patients who are coinfected with HIV-1 and HBV and have discontinued products containing emtricitabine and/or tenofovir disoproxil fumarate (TDF), and may occur with discontinuation of GENVOYA. Hepatic function should be monitored closely in these patients. If appropriate, anti-hepatitis B therapy may be warranted.
Used for
From the label: indications and usageGENVOYA is indicated as a complete regimen for the treatment of HIV-1 infection in adults and pediatric patients weighing at least 25 kg who have no antiretroviral treatment history or to replace the current antiretroviral regimen in those who are virologically-suppressed (HIV-1 RNA less than 50 copies per mL) on a stable antiretroviral regimen for at least 6 months with no history of treatment failure and no known s
Forms and strengths
- 150 mg / 150 mg / 200 mg / 10 mg
Tablet.
On the market
- Earliest approval on file
- November 5, 2015 Genvoya, Gilead Sciences Inc; Drugs@FDA’s file, where older or withdrawn approvals can be missing
- Generic approvals
- No generic approved
- Labelers listed (NDC)
- 1 of which 0 under generic applications, 1 under brand applications, repackagers included
- Last listed patent
- April 6, 2033 Genvoya tablets; not a generic launch date
Supply and safety
- Pharmacy cost (NADAC)
- $143.35 per tablet Genvoya tablet
- Shortage (FDA)
- No current entry
- Recalls by its makers (FDA)
- No recall recorded
- FAERS reports
- 10,002 through July 30, 2026
What is cobicistat, elvitegravir, emtricitabine and tenofovir alafenamide used for?
From the label: indications and usageGENVOYA is indicated as a complete regimen for the treatment of HIV-1 infection in adults and pediatric patients weighing at least 25 kg who have no antiretroviral treatment history or to replace the current antiretroviral regimen in those who are virologically-suppressed (HIV-1 RNA less than 50 copies per mL) on a stable antiretroviral regimen for at least 6 months with no history of treatment failure and no known substitutions associated with resistance to the individual components of GENVOYA [see Clinical Studies (14) ]. […]
Conditions named in the indications of cobicistat, elvitegravir, emtricitabine and tenofovir alafenamide's FDA labels, with every medicine labeled for each:
FDA pharmacologic class: Cytochrome P450 3A Inhibitor, Hepatitis B Virus Nucleoside Analog Reverse Transcriptase Inhibitor, Human Immunodeficiency Virus Integrase Strand Transfer Inhibitor and Human Immunodeficiency Virus Nucleoside Analog Reverse Transcriptase Inhibitor.
Source: FDA drug label (Genvoya), Gilead Sciences, Inc., effective February 3, 2025 (SPL set 34784acf-15ed-4715-b504-eb30430518e9), via openFDA; the full label on DailyMed
Is there a generic for cobicistat, elvitegravir, emtricitabine and tenofovir alafenamide (Genvoya)?
No generic cobicistat, elvitegravir, emtricitabine and tenofovir alafenamide is approved (Drugs@FDA, October 8, 2026).
The Orange Book lists 9 patents for Genvoya tablets: the compound patent runs to August 15, 2032 (pediatric exclusivity to February 15, 2033), and the last listed entry to April 6, 2033. A patent or exclusivity date is not the date a generic goes on sale: court cases and settlements move it either way.
- 2015 earliest approval on file
- 2033 last listed patent
Source: Drugs@FDA, FDA NDC Directory and the Orange Book (openFDA bulk files, October 8, 2026)
What do pharmacies pay for cobicistat, elvitegravir, emtricitabine and tenofovir alafenamide (Genvoya)?
In CMS's NADAC survey of October 7, 2026, pharmacies paid $143.35 per Genvoya tablet, up 5% from $136.65 on October 8, 2025. The chart's scale runs from the lowest to the highest price shown, not from zero. NADAC is what retail pharmacies paid their wholesalers, per unit, in CMS's monthly survey; what a patient pays depends on insurance and the pharmacy.
- Genvoya tablet (brand)
$143.35
$128.68
January 2024October 2026
| Strength and form | Brand or generic | Pharmacy cost | 30 tablets, or one pen or vial | 12-month change |
|---|---|---|---|---|
| Genvoya tablet | Brand | $143.35 per tablet | $4,300.60 | +5% |
Source: CMS National Average Drug Acquisition Cost (NADAC) survey, October 7, 2026: what retail pharmacies paid per unit; not a counter price
What does the cobicistat, elvitegravir, emtricitabine and tenofovir alafenamide label say about other medicines?
The cobicistat, elvitegravir, emtricitabine and tenofovir alafenamide label names 105 other medicines in its interaction, contraindication or warning sections. The sentences are the labels' own; a label lists what its studies and reports found, not every interaction.
| Medicine named | Section | What the label says |
|---|---|---|
| Acyclovir | drug interactions | Some examples of drugs that are eliminated by active tubular secretion include, but are not limited to, acyclovir, cidofovir, ganciclovir, valacyclovir, valganciclovir, aminoglycosides (e.g., gentamicin), and high-dose or multiple NSAIDs [see Warnings and Precautions (5.4) ]. |
| Alfuzosin | contraindications | Alpha 1-adrenoreceptor antagonist: alfuzosin Anticonvulsants: carbamazepine, phenobarbital, phenytoin Antimycobacterial: rifampin Antipsychotics: lurasidone, pimozide Ergot Derivatives: dihydroergotamine, ergotamine, methylergonovine Herbal Products: |
| Amiodarone | drug interactions | Concomitant Drug Class/Drug Name: Antiarrhythmics: e.g., amiodarone bepridil digoxin Indicates that a drug-drug interaction trial was conducted. disopyramide flecainide systemic lidocaine mexiletine propafenone quinidine; Effect on Concentration ↑ = Increase, ↓ = Decrease: ↑ antiarrhythmics ↑ digoxin; … |
| Amitriptyline | drug interactions | Concomitant Drug Class/Drug Name: Antidepressants: Selective Serotonin Reuptake Inhibitors (SSRIs) e.g., paroxetine Tricyclic Antidepressants (TCAs) e.g., amitriptyline desipramine imipramine nortriptyline bupropion trazodone; … |
| Amlodipine | drug interactions | Concomitant Drug Class/Drug Name: Calcium Channel Blockers: e.g., amlodipine diltiazem felodipine nicardipine nifedipine verapamil; Effect on Concentration ↑ = Increase, ↓ = Decrease: ↑ calcium channel blockers; … |
| Apixaban | drug interactions | Concomitant Drug Class/Drug Name: Anticoagulants: Direct Oral Anticoagulants (DOACs) apixaban rivaroxaban betrixaban dabigatran edoxaban; Effect on Concentration ↑ = Increase, ↓ = Decrease: ↑ apixaban; … |
| Atorvastatin | drug interactions | Concomitant Drug Class/Drug Name: atorvastatin; Effect on Concentration ↑ = Increase, ↓ = Decrease: ↑ atorvastatin; Clinical Comment: Initiate atorvastatin with the lowest starting dose of atorvastatin and titrate carefully while monitoring for safety (e.g., myopathy). … |
| Beclomethasone | drug interactions | … can increase the risk for Cushing's syndrome and adrenal suppression. Alternative corticosteroids including beclomethasone and prednisolone (whose PK and/or PD are less affected by strong CYP3A inhibitors relative to other studied steroids) should be considered, particularly for long-term use. |
| Betamethasone | drug interactions | Concomitant Drug Class/Drug Name: Corticosteroids: e.g., betamethasone budesonide ciclesonide dexamethasone fluticasone methylprednisolone mometasone prednisone triamcinolone; Effect on Concentration ↑ = Increase, ↓ = Decrease: ↓ elvitegravir ↓ cobicistat ↑ corticosteroids; … |
| Bosentan | drug interactions | Concomitant Drug Class/Drug Name: Endothelin Receptor Antagonists: bosentan; Effect on Concentration ↑ = Increase, ↓ = Decrease: ↑ bosentan; Clinical Comment: Coadministration of bosentan in patients on GENVOYA: In patients who have been receiving GENVOYA for at least 10 days, start bosentan at 62.5 mg once daily or … |
| Budesonide | drug interactions | Concomitant Drug Class/Drug Name: Corticosteroids: e.g., betamethasone budesonide ciclesonide dexamethasone fluticasone methylprednisolone mometasone prednisone triamcinolone; Effect on Concentration ↑ = Increase, ↓ = Decrease: ↓ elvitegravir ↓ cobicistat ↑ corticosteroids; … |
| Buprenorphine | drug interactions | Concomitant Drug Class/Drug Name: Narcotic Analgesics: buprenorphine/ naloxone; Effect on Concentration ↑ = Increase, ↓ = Decrease: ↑ buprenorphine ↑ norbuprenorphine ↓ naloxone; Clinical Comment: No dosage adjustment of buprenorphine/naloxone is required upon coadministration with GENVOYA. … |
| Buprenorphine and naloxone | drug interactions | Narcotic Analgesics: buprenorphine/ naloxone ↑ buprenorphine ↑ norbuprenorphine ↓ naloxone No dosage adjustment of buprenorphine/naloxone is required upon coadministration with GENVOYA. |
| Bupropion | drug interactions | Concomitant Drug Class/Drug Name: Antidepressants: Selective Serotonin Reuptake Inhibitors (SSRIs) e.g., paroxetine Tricyclic Antidepressants (TCAs) e.g., amitriptyline desipramine imipramine nortriptyline bupropion trazodone; … |
Every other medicine the cobicistat, elvitegravir, emtricitabine and tenofovir alafenamide label names
| Medicine named | Section | What the label says |
|---|---|---|
| Buspirone | drug interactions | Dosage reduction for midazolam should be considered, especially if more than a single dose of midazolam is administered. buspirone zolpidem With other sedative/hypnotics, dose reduction may be … |
| Carbamazepine | contraindications | Alpha 1-adrenoreceptor antagonist: alfuzosin Anticonvulsants: carbamazepine, phenobarbital, phenytoin Antimycobacterial: rifampin Antipsychotics: lurasidone, pimozide Ergot Derivatives … |
| Ciclesonide | drug interactions | Concomitant Drug Class/Drug Name: Corticosteroids: e.g., betamethasone budesonide ciclesonide dexamethasone fluticasone methylprednisolone mometasone prednisone triamcinolone; … |
| Cidofovir | drug interactions | Some examples of drugs that are eliminated by active tubular secretion include, but are not limited to, acyclovir, cidofovir, ganciclovir, valacyclovir, valganciclovir, aminoglycosides (e.g. … |
| Clarithromycin | drug interactions | Concomitant Drug Class/Drug Name: Antibacterials: clarithromycin telithromycin; Effect on Concentration ↑ = Increase, ↓ = Decrease: ↑ clarithromycin ↑ telithromycin ↑ cobicistat; … |
| Clopidogrel | drug interactions | Concomitant Drug Class/Drug Name: clopidogrel; Effect on Concentration ↑ = Increase, ↓ = Decrease: ↓ clopidogrel active metabolite; … |
| Clorazepate | drug interactions | Concomitant Drug Class/Drug Name: Other benzodiazepines: e.g., parenterally administered midazolam clorazepate diazepam estazolam flurazepam; … |
| Colchicine | drug interactions | Concomitant Drug Class/Drug Name: Anti-gout: colchicine; Effect on Concentration ↑ = Increase, ↓ = Decrease: ↑ colchicine; … |
| Cyclosporine | drug interactions | Concomitant Drug Class/Drug Name: Immuno-suppressants: e.g., cyclosporine (CsA) sirolimus tacrolimus; Effect on Concentration ↑ = Increase, ↓ = Decrease: ↑ immuno-suppressants ↑ elvitegravir (with … |
| Dabigatran | drug interactions | Concomitant Drug Class/Drug Name: Anticoagulants: Direct Oral Anticoagulants (DOACs) apixaban rivaroxaban betrixaban dabigatran edoxaban; … |
| Desipramine | drug interactions | … e.g., paroxetine Tricyclic Antidepressants (TCAs) e.g., amitriptyline desipramine imipramine nortriptyline bupropion trazodone; … |
| Dexamethasone | drug interactions | Concomitant Drug Class/Drug Name: Corticosteroids: e.g., betamethasone budesonide ciclesonide dexamethasone fluticasone methylprednisolone mometasone prednisone triamcinolone; … |
| Diazepam | drug interactions | Concomitant Drug Class/Drug Name: Other benzodiazepines: e.g., parenterally administered midazolam clorazepate diazepam estazolam flurazepam; … |
| Digoxin | drug interactions | Concomitant Drug Class/Drug Name: Antiarrhythmics: e.g., amiodarone bepridil digoxin Indicates that a drug-drug interaction trial was conducted. … |
| Dihydroergotamine | contraindications | … Antimycobacterial: rifampin Antipsychotics: lurasidone, pimozide Ergot Derivatives: dihydroergotamine, ergotamine, methylergonovine Herbal Products: |
| Diltiazem | drug interactions | Concomitant Drug Class/Drug Name: Calcium Channel Blockers: e.g., amlodipine diltiazem felodipine nicardipine nifedipine verapamil; … |
| Disopyramide | drug interactions | Concomitant Drug Class/Drug Name: Antiarrhythmics: e.g., amiodarone bepridil digoxin Indicates that a drug-drug interaction trial was conducted. … |
| Drospirenone | drug interactions | Concomitant Drug Class/Drug Name: Hormonal Contraceptives: drospirenone/ethinyl estradiol levonorgestrel norgestimate/ethinyl estradiol; … |
| Edoxaban | drug interactions | Concomitant Drug Class/Drug Name: Anticoagulants: Direct Oral Anticoagulants (DOACs) apixaban rivaroxaban betrixaban dabigatran edoxaban; … |
| Ergotamine | contraindications | … rifampin Antipsychotics: lurasidone, pimozide Ergot Derivatives: dihydroergotamine, ergotamine, methylergonovine Herbal Products: |
| Estazolam | drug interactions | Concomitant Drug Class/Drug Name: Other benzodiazepines: e.g., parenterally administered midazolam clorazepate diazepam estazolam flurazepam; … |
| Ethosuximide | drug interactions | Concomitant Drug Class/Drug Name: ethosuximide; Effect on Concentration ↑ = Increase, ↓ = Decrease: ↑ ethosuximide; Clinical Comment: Clinical monitoring is recommended upon coadministration of … |
| Famciclovir | drug interactions | … or are expected when GENVOYA is combined with the following drugs: famciclovir, famotidine, ledipasvir, methadone, omeprazole, prasugrel (active metabolite), sertraline, sofosbuvir, velpatasvir, and … |
| Famotidine | drug interactions | … expected when GENVOYA is combined with the following drugs: famciclovir, famotidine, ledipasvir, methadone, omeprazole, prasugrel (active metabolite), sertraline, sofosbuvir, velpatasvir, and … |
| Felodipine | drug interactions | Concomitant Drug Class/Drug Name: Calcium Channel Blockers: e.g., amlodipine diltiazem felodipine nicardipine nifedipine verapamil; … |
| Fentanyl | drug interactions | Concomitant Drug Class/Drug Name: fentanyl; Effect on Concentration ↑ = Increase, ↓ = Decrease: ↑ fentanyl; Clinical Comment: Careful monitoring of therapeutic and adverse effects of fentanyl … |
| Flecainide | drug interactions | … Indicates that a drug-drug interaction trial was conducted. disopyramide flecainide systemic lidocaine mexiletine propafenone quinidine; … |
| Flurazepam | drug interactions | Concomitant Drug Class/Drug Name: Other benzodiazepines: e.g., parenterally administered midazolam clorazepate diazepam estazolam flurazepam; … |
| Fluticasone | drug interactions | Concomitant Drug Class/Drug Name: Corticosteroids: e.g., betamethasone budesonide ciclesonide dexamethasone fluticasone methylprednisolone mometasone prednisone triamcinolone; … |
| Ganciclovir | drug interactions | Some examples of drugs that are eliminated by active tubular secretion include, but are not limited to, acyclovir, cidofovir, ganciclovir, valacyclovir, valganciclovir, aminoglycosides (e.g. … |
| Gentamicin | drug interactions | … ganciclovir, valacyclovir, valganciclovir, aminoglycosides (e.g., gentamicin), and high-dose or multiple NSAIDs [see Warnings and Precautions (5.4) ]. |
| Imipramine | drug interactions | … paroxetine Tricyclic Antidepressants (TCAs) e.g., amitriptyline desipramine imipramine nortriptyline bupropion trazodone; Effect on Concentration ↑ = Increase, ↓ = Decrease: ↑ SSRIs (except … |
| Itraconazole | drug interactions | Concomitant Drug Class/Drug Name: Antifungals: itraconazole ketoconazole voriconazole; Effect on Concentration ↑ = Increase, ↓ = Decrease: ↑ elvitegravir ↑ cobicistat ↑ itraconazole ↑ ketoconazole ↑ … |
| Ketoconazole | drug interactions | Concomitant Drug Class/Drug Name: Antifungals: itraconazole ketoconazole voriconazole; Effect on Concentration ↑ = Increase, ↓ = Decrease: ↑ elvitegravir ↑ cobicistat ↑ itraconazole ↑ ketoconazole ↑ … |
| Levonorgestrel | drug interactions | Concomitant Drug Class/Drug Name: Hormonal Contraceptives: drospirenone/ethinyl estradiol levonorgestrel norgestimate/ethinyl estradiol; … |
| Lidocaine | drug interactions | … interaction trial was conducted. disopyramide flecainide systemic lidocaine mexiletine propafenone quinidine; Effect on Concentration ↑ = Increase, ↓ = Decrease: ↑ antiarrhythmics ↑ digoxin; … |
| Lomitapide | contraindications | St. John's wort ( Hypericum perforatum ) Lipid-modifying Agents: lomitapide, lovastatin, simvastatin Phosphodiesterase-5 (PDE-5) Inhibitor: sildenafil when administered as REVATIO ® for the treatment … |
| Lovastatin | contraindications | St. John's wort ( Hypericum perforatum ) Lipid-modifying Agents: lomitapide, lovastatin, simvastatin Phosphodiesterase-5 (PDE-5) Inhibitor: sildenafil when administered as REVATIO ® for the treatment … |
| Lurasidone | contraindications | Alpha 1-adrenoreceptor antagonist: alfuzosin Anticonvulsants: carbamazepine, phenobarbital, phenytoin Antimycobacterial: rifampin Antipsychotics: lurasidone, pimozide Ergot Derivatives … |
| Methadone | drug interactions | … combined with the following drugs: famciclovir, famotidine, ledipasvir, methadone, omeprazole, prasugrel (active metabolite), sertraline, sofosbuvir, velpatasvir, and voxilaprevir. |
| Methylergonovine | contraindications | … lurasidone, pimozide Ergot Derivatives: dihydroergotamine, ergotamine, methylergonovine Herbal Products: |
| Methylprednisolone | drug interactions | Concomitant Drug Class/Drug Name: Corticosteroids: e.g., betamethasone budesonide ciclesonide dexamethasone fluticasone methylprednisolone mometasone prednisone triamcinolone; … |
| Metoprolol | drug interactions | Concomitant Drug Class/Drug Name: Beta-Blockers: e.g., metoprolol timolol; Effect on Concentration ↑ = Increase, ↓ = Decrease: ↑ beta-blockers; … |
| Mexiletine | drug interactions | … interaction trial was conducted. disopyramide flecainide systemic lidocaine mexiletine propafenone quinidine; Effect on Concentration ↑ = Increase, ↓ = Decrease: ↑ antiarrhythmics ↑ digoxin; … |
| Midazolam | contraindications | … arterial hypertension Sedative/hypnotics: triazolam, orally administered midazolam Coadministration of GENVOYA is contraindicated with drugs that: |
| Mometasone | drug interactions | Concomitant Drug Class/Drug Name: Corticosteroids: e.g., betamethasone budesonide ciclesonide dexamethasone fluticasone methylprednisolone mometasone prednisone triamcinolone; … |
| Naloxone | drug interactions | Concomitant Drug Class/Drug Name: Narcotic Analgesics: buprenorphine/ naloxone; Effect on Concentration ↑ = Increase, ↓ = Decrease: ↑ buprenorphine ↑ norbuprenorphine ↓ naloxone; … |
| Nicardipine | drug interactions | Concomitant Drug Class/Drug Name: Calcium Channel Blockers: e.g., amlodipine diltiazem felodipine nicardipine nifedipine verapamil; … |
| Nifedipine | drug interactions | Concomitant Drug Class/Drug Name: Calcium Channel Blockers: e.g., amlodipine diltiazem felodipine nicardipine nifedipine verapamil; … |
| Nortriptyline | drug interactions | … Antidepressants (TCAs) e.g., amitriptyline desipramine imipramine nortriptyline bupropion trazodone; Effect on Concentration ↑ = Increase, ↓ = Decrease: ↑ SSRIs (except sertraline) ↑ TCAs ↑ … |
| Omeprazole | drug interactions | … the following drugs: famciclovir, famotidine, ledipasvir, methadone, omeprazole, prasugrel (active metabolite), sertraline, sofosbuvir, velpatasvir, and voxilaprevir. |
| Oxcarbazepine | drug interactions | Concomitant Drug Class/Drug Name: oxcarbazepine; Effect on Concentration ↑ = Increase, ↓ = Decrease: Alternative anticonvulsants should be considered when GENVOYA is administered with oxcarbazepine. |
| Paroxetine | drug interactions | Concomitant Drug Class/Drug Name: Antidepressants: Selective Serotonin Reuptake Inhibitors (SSRIs) e.g., paroxetine Tricyclic Antidepressants (TCAs) e.g., amitriptyline desipramine imipramine … |
| Perphenazine | drug interactions | Concomitant Drug Class/Drug Name: Other antipsychotics e.g., perphenazine risperidone thioridazine; Effect on Concentration ↑ = Increase, ↓ = Decrease: ↑ antipsychotic; … |
| Phenobarbital | contraindications | Alpha 1-adrenoreceptor antagonist: alfuzosin Anticonvulsants: carbamazepine, phenobarbital, phenytoin Antimycobacterial: rifampin Antipsychotics: lurasidone, pimozide Ergot Derivatives … |
| Phenytoin | contraindications | Alpha 1-adrenoreceptor antagonist: alfuzosin Anticonvulsants: carbamazepine, phenobarbital, phenytoin Antimycobacterial: rifampin Antipsychotics: lurasidone, pimozide Ergot Derivatives … |
| Pimozide | contraindications | … phenytoin Antimycobacterial: rifampin Antipsychotics: lurasidone, pimozide Ergot Derivatives: dihydroergotamine, ergotamine, methylergonovine Herbal Products: |
| Prasugrel | drug interactions | … drugs: famciclovir, famotidine, ledipasvir, methadone, omeprazole, prasugrel (active metabolite), sertraline, sofosbuvir, velpatasvir, and voxilaprevir. |
| Prednisolone | drug interactions | Concomitant Drug Class/Drug Name: Corticosteroids: e.g., betamethasone budesonide ciclesonide dexamethasone fluticasone methylprednisolone mometasone prednisone triamcinolone; … |
| Prednisone | drug interactions | Concomitant Drug Class/Drug Name: Corticosteroids: e.g., betamethasone budesonide ciclesonide dexamethasone fluticasone methylprednisolone mometasone prednisone triamcinolone; … |
| Propafenone | drug interactions | … was conducted. disopyramide flecainide systemic lidocaine mexiletine propafenone quinidine; Effect on Concentration ↑ = Increase, ↓ = Decrease: ↑ antiarrhythmics ↑ digoxin; … |
| Quetiapine | drug interactions | Concomitant Drug Class/Drug Name: quetiapine; Effect on Concentration ↑ = Increase, ↓ = Decrease: ↑ quetiapine; Clinical Comment: Initiation of GENVOYA in patients taking quetiapine: Consider … |
| Quinidine | drug interactions | … disopyramide flecainide systemic lidocaine mexiletine propafenone quinidine; Effect on Concentration ↑ = Increase, ↓ = Decrease: ↑ antiarrhythmics ↑ digoxin; … |
| Rifabutin | drug interactions | Concomitant Drug Class/Drug Name: rifabutin rifapentine; Effect on Concentration ↑ = Increase, ↓ = Decrease: Coadministration of GENVOYA with rifabutin or rifapentine is not recommended. |
| Rifampin | contraindications | Alpha 1-adrenoreceptor antagonist: alfuzosin Anticonvulsants: carbamazepine, phenobarbital, phenytoin Antimycobacterial: rifampin Antipsychotics: lurasidone, pimozide Ergot Derivatives … |
| Rifapentine | drug interactions | Concomitant Drug Class/Drug Name: rifabutin rifapentine; Effect on Concentration ↑ = Increase, ↓ = Decrease: Coadministration of GENVOYA with rifabutin or rifapentine is not recommended. |
| Risperidone | drug interactions | Concomitant Drug Class/Drug Name: Other antipsychotics e.g., perphenazine risperidone thioridazine; Effect on Concentration ↑ = Increase, ↓ = Decrease: ↑ antipsychotic; … |
| Rivaroxaban | drug interactions | Concomitant Drug Class/Drug Name: Anticoagulants: Direct Oral Anticoagulants (DOACs) apixaban rivaroxaban betrixaban dabigatran edoxaban; … |
| Salmeterol | drug interactions | Concomitant Drug Class/Drug Name: Inhaled Beta Agonist: salmeterol; Effect on Concentration ↑ = Increase, ↓ = Decrease: ↑ salmeterol; … |
| Sertraline | drug interactions | … Effect on Concentration ↑ = Increase, ↓ = Decrease: ↑ SSRIs (except sertraline) ↑ TCAs ↑ trazodone; Clinical Comment: Careful dosage titration of the antidepressant and monitoring for antidepressant … |
| Sildenafil | contraindications | St. John's wort ( Hypericum perforatum ) Lipid-modifying Agents: lomitapide, lovastatin, simvastatin Phosphodiesterase-5 (PDE-5) Inhibitor: sildenafil when administered as REVATIO ® for the treatment … |
| Simvastatin | contraindications | St. John's wort ( Hypericum perforatum ) Lipid-modifying Agents: lomitapide, lovastatin, simvastatin Phosphodiesterase-5 (PDE-5) Inhibitor: sildenafil when administered as REVATIO ® for the treatment … |
| Sirolimus | drug interactions | Concomitant Drug Class/Drug Name: Immuno-suppressants: e.g., cyclosporine (CsA) sirolimus tacrolimus; Effect on Concentration ↑ = Increase, ↓ = Decrease: ↑ immuno-suppressants ↑ elvitegravir (with … |
| Sofosbuvir | drug interactions | … methadone, omeprazole, prasugrel (active metabolite), sertraline, sofosbuvir, velpatasvir, and voxilaprevir. |
| Sucralfate | drug interactions | … supplements, including multivitamins cation-containing antacids or laxatives sucralfate buffered medications; Effect on Concentration ↑ = Increase, ↓ = Decrease: ↓ elvitegravir; … |
| Tacrolimus | drug interactions | Concomitant Drug Class/Drug Name: Immuno-suppressants: e.g., cyclosporine (CsA) sirolimus tacrolimus; Effect on Concentration ↑ = Increase, ↓ = Decrease: ↑ immuno-suppressants ↑ elvitegravir (with … |
| Tadalafil | drug interactions | Concomitant Drug Class/Drug Name: Phosphodiesterase-5 (PDE5) Inhibitors: sildenafil tadalafil vardenafil; Effect on Concentration ↑ = Increase, ↓ = Decrease: ↑ PDE5 inhibitors; … |
| Thioridazine | drug interactions | Concomitant Drug Class/Drug Name: Other antipsychotics e.g., perphenazine risperidone thioridazine; Effect on Concentration ↑ = Increase, ↓ = Decrease: ↑ antipsychotic; … |
| Ticagrelor | drug interactions | Concomitant Drug Class/Drug Name: ticagrelor; Effect on Concentration ↑ = Increase, ↓ = Decrease: ↑ ticagrelor; Clinical Comment: Coadminstration with ticagrelor is not recommended. |
| Timolol | drug interactions | Concomitant Drug Class/Drug Name: Beta-Blockers: e.g., metoprolol timolol; Effect on Concentration ↑ = Increase, ↓ = Decrease: ↑ beta-blockers; … |
| Tramadol | drug interactions | Concomitant Drug Class/Drug Name: tramadol; Effect on Concentration ↑ = Increase, ↓ = Decrease: ↑ tramadol; Clinical Comment: A dose decrease may be needed for tramadol with concomitant use. |
| Trazodone | drug interactions | … e.g., amitriptyline desipramine imipramine nortriptyline bupropion trazodone; Effect on Concentration ↑ = Increase, ↓ = Decrease: ↑ SSRIs (except sertraline) ↑ TCAs ↑ trazodone; … |
| Triamcinolone | drug interactions | … dexamethasone fluticasone methylprednisolone mometasone prednisone triamcinolone; Effect on Concentration ↑ = Increase, ↓ = Decrease: ↓ elvitegravir ↓ cobicistat ↑ corticosteroids; … |
| Triazolam | contraindications | … the treatment of pulmonary arterial hypertension Sedative/hypnotics: triazolam, orally administered midazolam Coadministration of GENVOYA is contraindicated with drugs that: |
| Valacyclovir | drug interactions | Some examples of drugs that are eliminated by active tubular secretion include, but are not limited to, acyclovir, cidofovir, ganciclovir, valacyclovir, valganciclovir, aminoglycosides (e.g. … |
| Valganciclovir | drug interactions | … are not limited to, acyclovir, cidofovir, ganciclovir, valacyclovir, valganciclovir, aminoglycosides (e.g., gentamicin), and high-dose or multiple NSAIDs [see Warnings and Precautions (5.4) ]. |
| Vardenafil | drug interactions | Concomitant Drug Class/Drug Name: Phosphodiesterase-5 (PDE5) Inhibitors: sildenafil tadalafil vardenafil; Effect on Concentration ↑ = Increase, ↓ = Decrease: ↑ PDE5 inhibitors; … |
| Verapamil | drug interactions | Concomitant Drug Class/Drug Name: Calcium Channel Blockers: e.g., amlodipine diltiazem felodipine nicardipine nifedipine verapamil; … |
| Voriconazole | drug interactions | Concomitant Drug Class/Drug Name: Antifungals: itraconazole ketoconazole voriconazole; Effect on Concentration ↑ = Increase, ↓ = Decrease: ↑ elvitegravir ↑ cobicistat ↑ itraconazole ↑ ketoconazole ↑ … |
| Warfarin | drug interactions | Concomitant Drug Class/Drug Name: warfarin; Effect on Concentration ↑ = Increase, ↓ = Decrease: Effect on warfarin unknown; … |
| Zolpidem | drug interactions | Dosage reduction for midazolam should be considered, especially if more than a single dose of midazolam is administered. buspirone zolpidem With other sedative/hypnotics, dose reduction may be … |
Check cobicistat, elvitegravir, emtricitabine and tenofovir alafenamide against other medicines
Source: FDA drug label (Genvoya), Gilead Sciences, Inc., effective February 3, 2025 (SPL set 34784acf-15ed-4715-b504-eb30430518e9), via openFDA; the full label on DailyMed
What do FAERS reports show for cobicistat, elvitegravir, emtricitabine and tenofovir alafenamide?
The FDA Adverse Event Reporting System holds 10,002 reports that list cobicistat, elvitegravir, emtricitabine and tenofovir alafenamide among the medicines taken, through July 30, 2026, each a report of something that happened, not proof the medicine caused it; 199 are coded as a death and 1,140 as a hospital stay. Counts follow how widely a medicine is used and watched, and they are not a measure of how risky it is. Reports rose sharply in 2020 (4,081, against a median of 524 a year): FAERS counts follow reporting, which news, litigation and label changes can drive, not how often a reaction happens.
Reports received each year
The most reported reactions
Source: FDA Adverse Event Reporting System (FAERS) via openFDA, reports through July 30, 2026
What else is labeled for the same conditions as cobicistat, elvitegravir, emtricitabine and tenofovir alafenamide?
32 other medicines are given the same way (oral) and in the same FDA class as cobicistat, elvitegravir, emtricitabine and tenofovir alafenamide or labeled mainly for the same use (HIV), the same class first. HIV lists all 47 medicines labeled for it, by any route. The first 8 are below. They are listed as records, not as substitutes: whether one can replace another is a prescriber's decision.
| Medicine | Shared indication | Generic labelers (oral) | Pharmacy cost | Shortage |
|---|---|---|---|---|
| Lamivudine | HIV | 14 labelers | $0.489 per tablet 150 mg tablet | No current entry |
| Tenofovir disoproxil | HIV | 15 labelers | $0.294 per tablet 300 mg tablet | No current entry |
| Abacavir | HIV | 12 labelers | $0.546 per tablet 300 mg tablet | No current entry |
| Lamivudine and zidovudine | HIV | 7 labelers | $0.771 per tablet Lamivudine-zidovudine tablet | No current entry |
| Ritonavir | HIV | 7 labelers | $0.607 per tablet 100 mg tablet | A presentation being discontinued |
| Lopinavir and ritonavir | HIV | 3 labelers | $4.46 per tablet 200-50 mg tablet | A presentation being discontinued |
| Raltegravir | HIV | 1 labeler | $34.54 per tablet 400 mg tablet | No current entry |
| Zidovudine | HIV | 3 labelers | $0.464 per tablet 300 mg tablet | No current entry |
Source: FDA drug labels (indications), NDC Directory, NADAC of October 7, 2026, FDA shortages (October 8, 2026)
What next?
- Alternatives to cobicistat, elvitegravir, emtricitabine and tenofovir alafenamide
- 32 medicines for the same use
- Other cytochrome p450 3a inhibitors
- the pharmacologic class, with prices and generics
- Cobicistat, elvitegravir, emtricitabine and tenofovir alafenamide side effects
- the label's list beside FAERS reports
- Check an interaction
- what two or more labels say about each other